A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Original (black can with green logo) Zero Sugar (originally had dark blue logo; changed to resemble Original can with the top recolored green with a black pull tab) Lo-Carb (black can with dark blue logo) Assault (cola flavor, stylized camouflage can with red logo) Reserve White Pineapple (pineapple flavor, black can with yellow logo and yellow band around flavor title) Reserve Orange Dreamsicle (orange flavor, black can with orange logo) Reserve Watermelon (watermelon flavor, black can with red logo) Ripper (tropical fruits flavor, yellow can) Cuba-Libre (cola and lime flavor version of the cuba libre cocktail.) Dub Mad Dog (grape flavor, discontinued) Maxx (original flavor with added nitrous oxide, comes in a variety of flavors) Nitro Super Dry (citrus flavor; utilizes nitrous oxide rather than carbon dioxide, giving the beverage a light & dry texture (mouthfeel) similar to that of fine champagne, black can with black logo shrouded in lime green) Mule (ginger beer flavor, zero sugar, matte finish black can with bronze logo and text with 'Non-alcoholic', inspired to the Moscow Mule cocktail) VR46 The Doctor (orange flavor, yellow can with Valentino Rossi's The Doctor branding) LH44 Lewis Hamilton (red can with yellow and black patterns with black logo) Full Throttle (previously named Lewis Hamilton too, blue can with white text and yellow logo) Java (Coffee mixed with Monster Energy available in a variety of flavors including salted caramel, loca moca, Irish cream, and mean bean.) Pacific Punch (cherry punch flavor) Pipeline Punch (passion fruit, orange and guava flavor, pink can) Mixxd (Punch line. Cherry flavor, surface-textured purple can.) Monarch (juiced line, pastel pink can with yellow logo and Monarch butterfly artwork) Mango Loco (juiced line, blue can with orange logo and artwork themed to the Mexican Day of the Dead) Khaotic (juiced line, yellow can with light blue logo and graffiti butterfly artwork) Aussie Lemonade style (Juiced line, blue can with yellow logo and artwork featuring a variety of sea creatures. Citrus flavored. Introduced in 2022) Bad Apple (juiced line, red apple flavor, punky/alt version of Eve holding an apple) Rio Punch™ (juice line, sweet papaya, vanilla ice cream, hint of blackcurrant, green can with yellow diamond themed to the Brazilian flag.) Viking Berry™ (juice line, mixed nordic berries, blackberry, black currant, hint of lingonberry, sweet and tart profile, red and light blue can with norse themed art.) Voodoo Grape™ (juice line, Concord, Niagara, and red grape profile, yellow and purple can with Louisiana voodoo-themed artwork) Zero Ultra (citrus flavor, zero sugar, textured white can with silver logo) Commonly known as "White Monster" Lando Norris Zero Sugar (melon yuzu flavour, black can with neon yellow pattern) Ultra Blue (blue raspberry flavor with a light citrus and berry flavor profile, zero sugar, textured light blue can with silver logo) Ultra Fantasy Ruby Red (grapefruit flavor, zero sugar, textured magenta can with silver logo) Ultra Fiesta (mango flavor, zero sugar, textured blue can with silver logo) Ultra Watermelon (watermelon flavor, zero sugar, textured bright red can with silver logo) Ultra Paradise (apple and kiwi flavor, zero sugar, textured lime green can with silver logo) Ultra Rosá (pink lemonade flavor, zero sugar, textured hot pink can with silver logo) Ultra Gold (pineapple flavor, zero sugar, textured gold can with silver logo) Ultra Vice Guava (guava flavor, zero sugar, textured teal can with pink-white logo) Ultra Red (mixed berry flavor, zero sugar, red can) Ultra Black (cherry flavor, zero sugar, textured black can with silver logo) Ultra Peachy Keen (Peach flavor, zero sugar, textured peach can with silver logo. Made in limited edition form.) Ultra Sunrise (Orange flavor, zero sugar, orange can with silver logo) Ultra Strawberry Dreams (strawberry flavor, zero sugar, pink can) Ultra Passion (passionfruit flavour) Ultra Red, White, and Blue (rocket pop flavour) Ultra Violet, a.k.a. The Purple Monster (grape flavor, zero sugar, violet can)
In the 1980s, 10-year-old Enric and his 8-year-old sister, Irene, are dragged away from their father by their mother, Montserrat, a volatile woman struggling with stability. Montserrat’s reckless lifestyle and severe neglect traumatize the children. Following a devastating apartment fire that leaves Irene facial scarring and rendered mute, Montserrat relocates the family to a remote, isolated villa with Pep Puig, a religious fanatic. Pep renames the children Isaías and Resurrección, imposing strict religious rules that forbid them from ever leaving the house or making contact with the outside world. By 1996, Isaías (Enric) and Resurrección (Irene) help raise their six younger sisters — Aina, Julia, Cecilia, Neus, Beth and Nora — under Pep and Montserrat's severe isolation. As Montserrat’s mental health deteriorates into grandiose delusions, she claims to speak directly with God and forces her daughters into a Christian pop group called Stella Maris to fulfill a "divine mission to save humanity." Enric secretly introduces his sisters to musical movies using a stolen VHS tape and camera, but after Montserrat discovers this, she locks him in the basement and escalates her religious rule. Brief interventions by Social Services and temporary schooling fail to free the family; after a failed mass suicide attempt orchestrated by Montserrat, Enric is framed for an attack, thrown out of the house, and flees to Barcelona. In 2012, an adult Enric spots a viral Stella Maris video on the news, prompting him to seek out Irene and attempt to rescue their younger sisters.
Durston had attempted to treat Travers with salivation, which he believed reduced her breasts slightly but which she did not like as a treatment option, and then cauterization followed by incision by knife in the hope that excess fluid would be found to drain, but this was unsuccessful as it was healthy breast tissue, notable only for its massive enlargement and thus lacking excess fluid to drain.
ASH New Zealand stated that earlier increases in youth vaping occurred during a period before vaping products were comprehensively regulated in late 2020. In Canada reported that past-30-day vaping among youth aged 12–17 declined from 13.2% in 2019 to 7.2% in 2023. Health Canada also set a target of reducing vaping prevalence among those aged 12 to 17 to below 10% by 2025.
Sources: en.wikipedia.org
Validation and verification of medical devices ensure that they fulfil their intended purpose. Validation or verification is generally needed when a health facility acquires a new device to perform medical tests. The main difference between the two is that validation is focused on ensuring that the device meets the needs and requirements of its intended users and the intended use environment, whereas verification is focused on ensuring that the device meets its specified design requirements.
== Medical uses == CPA is used as a progestin and antiandrogen in hormonal birth control and in the treatment of androgen-dependent conditions. Specifically, CPA is used in combined birth control pills, in the treatment of androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss, high androgen levels, in transgender hormone therapy, to treat prostate cancer, to reduce sex drive in sex offenders or men with paraphilias or hypersexuality, to treat early puberty, and for other uses. Treatment dosages range from 2mg or less, to 100mg or more daily. In the United States, where CPA is not available, other medications with antiandrogenic effects are used to treat androgen-dependent conditions instead. Examples of such medications include gonadotropin-releasing hormone modulators (GnRH modulators) like leuprorelin and degarelix, nonsteroidal antiandrogens like flutamide and bicalutamide, the diuretic and steroidal antiandrogen spironolactone, the progestin medroxyprogesterone acetate, and the 5α-reductase inhibitors finasteride and dutasteride. The steroidal antiandrogen and progestin chlormadinone acetate is used as an alternative to CPA in Japan, South Korea, and a few other countries. In 2020, the European Medicine Agency issued a warning that high doses of cyproterone acetate (25mg daily or more) may contribute to risk of meningioma, and recommended physicians use alternative treatment for most indications (or the minimum effective dose where no alternatives were available) with the exception of prostate carcinoma.
=== Vascular malformations === Sirolimus is used to treat vascular malformations. Treatment with sirolimus can decrease pain and the fullness of vascular malformations, improve coagulation levels, and slow the growth of abnormal lymphatic vessels. Sirolimus is a relatively new medical therapy for the treatment of vascular malformations in recent years, sirolimus has emerged as a new medical treatment option for both vascular tumors and vascular malformations, as a mammalian target of rapamycin (mTOR), capable of integrating signals from the PI3K/AKT pathway to coordinate proper cell growth and proliferation. Hence, sirolimus is ideal for "proliferative" vascular tumors through the control of tissue overgrowth disorders caused by inappropriate activation of the PI3K/AKT/mTOR pathway as an antiproliferative agent.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.